19 Mar 2019 --- Sustainable ingredients company Amyris has revealed LAVVAN as its partner in a US$300 million deal for the development of a new cannabinoid. The announcement comes alongside the preliminary unaudited financial results for its fourth quarter and fiscal year 2018, which ended on December 31, 2018. The results are reportedly “below expectations.” In the hours following the disclosure of LAVVAN as its CBD partner, Amyris’ stock reportedly went up by 20 percent.
